Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Bang, Yung-Jue

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Nov 2015 - 3858-65 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1527-7755

10.1200/JCO.2014.60.0320 doi


Adenocarcinoma--classification
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Ataxia Telangiectasia Mutated Proteins--blood
Biomarkers, Tumor--blood
Biopsy, Needle
Disease-Free Survival
Double-Blind Method
Female
Follow-Up Studies
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local--classification
Paclitaxel--administration & dosage
Phthalazines--administration & dosage
Piperazines--administration & dosage
Proportional Hazards Models
Prospective Studies
Stomach Neoplasms--classification
Survival Analysis
Treatment Outcome